Straits Times Index
3,322.62 +14.72 (+0.45%) S&P 500
5,307.01 -14.40 (-0.27%) Dow
39,671.04 -201.95 (-0.51%) Nasdaq
16,801.54 -31.08 (-0.18%) Bitcoin USD
69,868.66 -62.52 (-0.09%) CMC Crypto 200
1,512.83 +10.17 (+0.68%)
CLDX Jan 2025 23.000 call
| Previous close | 10.10 |
| Open | N/A |
| Bid | 10.00 |
| Ask | 14.80 |
| Strike | 23.00 |
| Expiry date | 2025-01-17 |
| Day's range | 10.10 - 10.10 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
GlobeNewswireCelldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
HAMPTON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company’s Phase 2 subcutaneous study of barzolvolimab in prurigo nodularis (PN). Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for the function and survival of the mast cell. Mast cells are believed to play an impo
ZacksWall Street Analysts Believe Celldex (CLDX) Could Rally 67.77%: Here's is How to Trade
The consensus price target hints at a 67.8% upside potential for Celldex (CLDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Simply Wall St.Celldex Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Celldex Therapeutics ( NASDAQ:CLDX ) First Quarter 2024 Results Key Financial Results Net loss: US$32.8m (loss widened...
